Sarepta is rebuilding a commercial-stage rare-disease business around ELEVIDYS and its established PMO therapies after a major safety and regulatory disruption; management’s 2026 plan calls for stabilizing growth while advancing the broader pipeline.
The litigation overhang is now converted into a known cost. Sarepta had already recorded a $39.0 million contingency charge for the anticipated settlement, and the final agreement requires the same $39.0 million lump-sum payment within ten days.
| Item | Filing detail |
|---|---|
| Settlement payment | $39.0 million (Item 1.01) |
| Prior accounting charge | $39.0 million contingency charge (Item 1.01) |
| Payment timing | Within 10 days of September 23, 2026 (Item 1.01) |
The important value is not the payment; it is the protection around ELEVIDYS. REGENXBIO and UPenn release existing infringement claims covering Sarepta’s AAVrh74-based products, including ELEVIDYS, and agree not to pursue related claims going forward. 〔0〕 〔1〕
This is partly new, not a surprise settlement. The charge shows Sarepta had already signaled that a deal was likely, so the market should not treat the $39 million as an unexpected hit. The incremental news is the breadth and finality of the covenant not to sue, including protection for the existing ELEVIDYS form and AAVrh74 capsid sequence; the litigations will be disposed of with prejudice. 〔2〕 〔3〕
Bottom line: This removes a meaningful legal uncertainty around Sarepta’s core gene-therapy product at an already-reserved cost. It advances the ELEVIDYS commercialization story modestly rather than changing the company’s financial outlook outright.
Read the original 8-K on SEC EDGAR ↗